Navigation Links
Cempra Announces Comparable Efficacy of Oral Solithromycin (CEM-101) Compared with Levofloxacin in Phase II Clinical Trial in Patients with Community-Acquired Bacterial Pneumonia (CABP)
Date:9/15/2011

CHAPEL HILL, N.C., Sept. 15, 2011 /PRNewswire/ -- Cempra Pharmaceuticals today announced results from its Phase II clinical trial investigating the efficacy, safety and tolerability of oral administration of our fourth generation macrolide, solithromycin (CEM-101), a fluoroketolide antibiotic, in comparison with oral levofloxacin for the treatment of community-acquired bacterial pneumonia (CABP).  In the Phase II trial, CEM-101 demonstrated efficacy comparable to levofloxacin and a favorable safety and tolerability profile, with a lower incidence of treatment emergent adverse events than levofloxacin.  

"Macrolides have been an important therapeutic option for physicians to use for the treatment of bacterial pneumonia and other infections, but antimicrobial resistance has been increasing among the major pathogens which cause these infections," said Professor Robert Moellering, M.D., Shields Warren-Mallinckrodt Professor of Medical Research at Harvard Medical School.  "A safe macrolide as potent as CEM-101 has the potential of being a very useful agent."

David Oldach, M.D., senior vice president of clinical research of Cempra added, "Results from this trial indicate that CEM-101 is a product candidate with efficacy comparable to levofloxacin, the current standard of care for the treatment of CABP and with a favorable safety profile.  We believe these data validate the dosing strategy of CEM-101 employed in this trial and strongly support progression into Phase III trials. We look forward to presenting the full data set at an upcoming scientific conference."

Study Design

The trial was a randomized double-blind, multi-center study to evaluate the efficacy and safety of oral CEM-101 compared to oral levofloxacin in the treatment of patients with CABP.  One hundred thirty two patients were randomized to receive either CEM-101 (800 mg on Day 1 followed by 400 mg on Days 2 to 5) or levofloxacin (750 mg on Days
'/>"/>

SOURCE Cempra Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cempra Pharmaceuticals to Present at the 2011 Wells Fargo Healthcare Conference
2. Cempra Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
3. Cempra Pharmaceuticals to Present at Two Investor Conferences in Paris
4. Intravenous (IV) Administration of Cempra Pharmaceuticals Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial
5. Cempra Pharmaceuticals to Present at Two Upcoming Cambridge Healthtech Institute (CHI) Conferences
6. Cempra Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Cempra Expands Clinical Management Team to Advance Leading Antibacterial Clinical Programs Solithromycin and TAKSTA™
8. Cempra Pharmaceuticals Names Carl Foster Executive Vice President of Business Development
9. Cempra Pharmaceuticals Names Richard Kent, M.D., to Its Board of Directors
10. Cempra Pharmaceuticals to Present at the UBS Global Life Sciences Conference
11. Cempra Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... , Aug. 4, 2015 Among 1,000 ... medications, yet only half of consumers surveyed are aware ... have ever used use them, according to findings from ... a community service partnership focused on improving the health ... The online survey polled 1,000 men and women, ages ...
(Date:8/4/2015)... Wis. , Aug. 4, 2015  Ironshore ... agreement with Restore Health, a company specializing in ... a double-blind clinical trial, designed to evaluate the ... in development to treat Attention-deficit/hyperactivity disorder (ADHD). This ... Restore Health originally partnered with Ironshore ...
(Date:8/3/2015)... GLENWOOD, Ill. , Aug. 3, 2015  Landauer, ... personal and environmental radiation measurement and monitoring, outsourced medical ... announced it will release financial results for the fiscal ... August 10, 2015. The Company will ... August 11, 2015 at 9:00 a.m. Central Time (10:00 ...
Breaking Medicine Technology:New Study Finds Consumers are Leaving Money at the Pharmacy 2New Study Finds Consumers are Leaving Money at the Pharmacy 3Restore Health Secures Another Clinical Trial with Ironshore Pharmaceuticals & Development 2Landauer, Inc. Announces Date And Time For Announcement Of Fiscal Third Quarter 2015 Results And Conference Call 2
... cancer is the world,s most common cancer, and an estimated ... It is also estimated that lung cancer will cause 159,000 ... the total number of deaths resulting from breast, colon and ... cancers in both awareness and research funding, and, partly due ...
... LLC, a customer service focused clinical research organization, ... company as Senior Vice President of Clinical Operations. ... years of clinical research experience in multiple therapeutic ... nervous system, oncology, etc. , In her new ...
Cached Medicine Technology:November is Lung Cancer Month: Know the Latest Information About This Deadliest of Cancers 2November is Lung Cancer Month: Know the Latest Information About This Deadliest of Cancers 3November is Lung Cancer Month: Know the Latest Information About This Deadliest of Cancers 4November is Lung Cancer Month: Know the Latest Information About This Deadliest of Cancers 5ClinOps, LLC Enhances Senior Management Team With Addition of Connie Andrews as Senior Vice President of Clinical Operations 2
(Date:8/4/2015)... ... , ... METTLER TOLEDO has announced an upcoming online symposium ... Pfizer, and Merck. This free online seminar will be held on September ... informed decisions with limited process understanding. Established methods have been developed to ...
(Date:8/4/2015)... ... 04, 2015 , ... Half of consumers are considering a ... increasingly influential in their choice of practitioner, according to new survey data from ... Cosmetic Dermatologic Procedures reflects overall consumer views on cosmetic medical treatments and ratings ...
(Date:8/4/2015)... ... ... The results of a three year clinical trial for the Argus II, a ... blindness, were published on June 23, 2015 in Ophthalmology , the journal of ... more commonly known as the “bionic eye,” is safe and effective for long-term treatment ...
(Date:8/4/2015)... ... August 04, 2015 , ... Rock Your Hair, http://www.rockyourhair.com ... Bash Tour. In addition, they have signed Lexi Noel, dubbed the Teen Beauty Queen ... print and overall branding opportunities for the company. , The Pop & Rock ...
(Date:8/4/2015)... , ... August 04, 2015 , ... More than 700 ... renewed their wedding vows on Friday, July 24th. Chaplains Shawn Kafader and Richard ... each other. Following the ceremony was a reception, with music by the Moonlight ...
Breaking Medicine News(10 mins):Health News:METTLER TOLEDO Announces New Process Chemistry and Scale-up Online Seminar 2Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 2Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 3Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 4Health News:“Bionic Eye” Implant for the Blind Proved Safe and Effective at the End of a Three Year Clinical Trial 2Health News:Rock Your Hair Signs On As Title Sponsor For The HYPE! Projects Pop & Rock Beauty Bash Tour 2Health News:Couples Renew Vows at Friendship Village of Schaumburg 2
... one-fifth of primary care physicians in the US follow ... tests they recommend, according to Dr. Robin Yabroff from ... percent followed guidelines for some of the tests they ... guidelines for any of the screening tests they recommended. ...
... Randy Dotinga HealthDay Reporter , WEDNESDAY, Oct. 13 ... in poor countries could help HIV-infected mothers and their infants ... Currently, doctors lower the risk of transmission of mother-to-baby HIV ... and to babies right after. About half of the babies ...
... Ore According to new research conducted at Oregon ... power to combat fibromyalgia a medical disorder characterized ... in the November 10 online edition of the journal ... "Previous research suggests that the most successful treatment ...
... both medical progress and unmet needs in the ... Philadelphia will house the Network Coordinating Center for ... Research Network. Launched this year with ... federal government,s Maternal Child Health Bureau, the Network ...
... HealthDay Reporter , WEDNESDAY, Oct. 13 (HealthDay News) -- ... brain shrinkage in old age, which in turn helps stem ... reveals. "We have always been in search of the ... noted Kirk I. Erickson, an assistant professor of psychology at ...
... Gordon HealthDay Reporter , WEDNESDAY, Oct. 13 (HealthDay ... Virginia may have elevated blood pressure, according to new research ... "The real thrust of this research is trying to ... screen for hypertension [high blood pressure] in children. And, while ...
Cached Medicine News:Health News:Not all doctors follow cancer screening guidelines 2Health News:Studies Tout Alternative HIV Regimens for Women, Babies 2Health News:Studies Tout Alternative HIV Regimens for Women, Babies 3Health News:OHSU research suggests yoga can counteract fibromyalgia 2Health News:Children's Hospital coordinates new network for developmental disabilities 2Health News:Walking 6 to 9 Miles a Week May Help Save Memory 2Health News:Walking 6 to 9 Miles a Week May Help Save Memory 3Health News:Nearly 1 in 5 W.Va. 5th Graders May Have High Blood Pressure 2Health News:Nearly 1 in 5 W.Va. 5th Graders May Have High Blood Pressure 3
Inquire...
Inquire...
... new QIAvac 24 Plus vacuum manifold allows processing of ... tedious loading and unloading of spin columns into and ... Plus offers: Time savings ... DNA, PCR products, and RNA Convenience ...
... Vac Manifold is available to ... 30 minutes; the manifold is ... and a vacuum regulator with ... vacuum chamber, on/off switch, control ...
Medicine Products: